国: アメリカ合衆国
言語: 英語
ソース: NLM (National Library of Medicine)
METFORMIN HYDROCHLORIDE (UNII: 786Z46389E) (METFORMIN - UNII:9100L32L2N)
Major Pharmaceuticals
METFORMIN HYDROCHLORIDE
METFORMIN HYDROCHLORIDE 500 mg
ORAL
PRESCRIPTION DRUG
Metformin hydrochloride tablets USP is indicated as an adjunct to diet and exercise to improve glycemic control in adults and children with type 2 diabetes mellitus. Metformin hydrochloride is contraindicated in patients with: Metformin hydrochloride should be temporarily discontinued in patients undergoing radiologic studies involving intravascular administration of iodinated contrast materials, because use of such products may result in acute alteration of renal function. (See also PRECAUTIONS. )
Metformin hydrochloride tablets USP: Metformin hydrochloride tablets 500 mg are white to off-white, round shape, biconvex coated tablets debossed with "227" on one side and plain on the other side. Bottles of 100 : NDC 67877-217-01 Bottles of 500 : NDC 67877-217-05 Bottles of 1000 : NDC 67877-217-10 Metformin hydrochloride tablets 850 mg are white to off-white, round shape, biconvex coated tablets debossed with "228" on one side and plain on the other side. Bottles of 100 : NDC 67877-218-01 Bottles of 500 : NDC 67877-218-05 Bottles of 1000 : NDC 67877-218-10 Metformin hydrochloride tablets 1000 mg are white to off white, oval, capsule shaped, biconvex, coated tablets debossed with “229/229” on one side and a bisect line on both sides. Bottles of 100 : NDC 67877-221-01 Bottles of 500 : NDC 67877-221-05 Bottles of 1000 : NDC 67877-221-10 Store at 20°–25° C (68°–77° F); excursions permitted to 15°–30° C (59°–86° F). [See USP Controlled Room Temperature.] Dispense in light-resistant containers. Manufactured by: Alkem Laboratories Limited ALKEM HOUSE, Lower Parel, Mumbai – 400 013, INDIA May, 2012 Distributed by: Ascend Laboratories, LLC. Montvale, NJ 07645 Distributed by: MAJOR® PHARMACEUTICALS Livonia, MI 48150 REFER TO PACKAGE LABEL FOR DISTRIBUTOR"S NDC NUMBER PT1260-04
Abbreviated New Drug Application
METFORMIN HYDROCHLORIDE- METFORMIN HYDROCHLORIDE TABLET, FILM COATED MAJOR PHARMACEUTICALS ---------- METFORMIN HYDROCHLORIDE TABLETS USP BOXED WARNING LACTIC ACIDOSIS: LACTIC ACIDOSIS IS A RARE, BUT SERIOUS, METABOLIC COMPLICATION THAT CAN OCCUR DUE TO METFORMIN ACCUMULATION DURING TREATMENT WITH METFORMIN; WHEN IT OCCURS, IT IS FATAL IN APPROXIMATELY 50% OF CASES. LACTIC ACIDOSIS MAY ALSO OCCUR IN ASSOCIATION WITH A NUMBER OF PATHOPHYSIOLOGIC CONDITIONS, INCLUDING DIABETES MELLITUS, AND WHENEVER THERE IS SIGNIFICANT TISSUE HYPOPERFUSION AND HYPOXEMIA. LACTIC ACIDOSIS IS CHARACTERIZED BY ELEVATED BLOOD LACTATE LEVELS (>5 MMOL/ L), DECREASED BLOOD PH, ELECTROLYTE DISTURBANCES WITH AN INCREASED ANION GAP, AND AN INCREASED LACTATE/PYRUVATE RATIO. WHEN METFORMIN IS IMPLICATED AS THE CAUSE OF LACTIC ACIDOSIS, METFORMIN PLASMA LEVELS >5 ΜG/ML ARE GENERALLY FOUND. THE REPORTED INCIDENCE OF LACTIC ACIDOSIS IN PATIENTS RECEIVING METFORMIN HYDROCHLORIDE IS VERY LOW (APPROXIMATELY 0.03 CASES/1000 PATIENT-YEARS, WITH APPROXIMATELY 0.015 FATAL CASES/1000 PATIENT-YEARS). IN MORE THAN 20,000 PATIENT-YEARS EXPOSURE TO METFORMIN IN CLINICAL TRIALS, THERE WERE NO REPORTS OF LACTIC ACIDOSIS. REPORTED CASES HAVE OCCURRED PRIMARILY IN DIABETIC PATIENTS WITH SIGNIFICANT RENAL INSUFFICIENCY, INCLUDING BOTH INTRINSIC RENAL DISEASE AND RENAL HYPOPERFUSION, OFTEN IN THE SETTING OF MULTIPLE CONCOMITANT MEDICAL/SURGICAL PROBLEMS AND MULTIPLE CONCOMITANT MEDICATIONS. PATIENTS WITH CONGESTIVE HEART FAILURE REQUIRING PHARMACOLOGIC MANAGEMENT, IN PARTICULAR THOSE WITH UNSTABLE OR ACUTE CONGESTIVE HEART FAILURE WHO ARE AT RISK OF HYPOPERFUSION AND HYPOXEMIA, ARE AT INCREASED RISK OF LACTIC ACIDOSIS. THE RISK OF LACTIC ACIDOSIS INCREASES WITH THE DEGREE OF RENAL DYSFUNCTION AND THE PATIENT'S AGE. THE RISK OF LACTIC ACIDOSIS MAY, THEREFORE, BE SIGNIFICANTLY DECREASED BY REGULAR MONITORING OF RENAL FUNCTION IN PATIENTS TAKING METFORMIN AND BY USE OF THE MINIMUM EFFECTIVE DOSE OF METFORMIN. IN PARTICULAR, TREATMENT OF THE ELDERLY SHOULD BE ACCOMPA 完全なドキュメントを読む